Quince Therapeutics downgraded by Citizens JMP
$QNCX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citizens JMP downgraded Quince Therapeutics from Mkt Outperform to Mkt Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2026 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 8/5/2025 | $9.00 | Mkt Outperform | Citizens JMP |
| 3/24/2025 | $10.00 | Outperform | Oppenheimer |
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD of 67.4 meters and PVR reduction of 33.9% at 24 weeksPhase 2b trial in PH-ILD to initiate in mid-2026, with topline data anticipated in the first quarter of 2028Conference call and webcast today, May 18, 2026, at 10:00 a.m. ET SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (NASDAQ:QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), in patients with pulmonary arterial hypertension (
Acquisition includes LAM-001, an inhaled formulation of rapamycin for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome post lung transplant (BOS)$115 million in upfront financing with the potential to receive up to an additional $72 million upon exercise of accompanying warrantsUpfront proceeds from the private placement and existing cash and cash equivalents at closing are expected to fund operations through the end of 2028 and to support multiple expected milestones, including initiation of a Phase 2b trial in PH-ILD with data anticipated in Q1 2028 and delivery of Phase 2 data in BOS in Q
Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD of 67.4 meters and PVR reduction of 33.9% at 24 weeksPhase 2b trial in PH-ILD to initiate in mid-2026, with topline data anticipated in the first quarter of 2028Conference call and webcast today, May 18, 2026, at 10:00 a.m. ET SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (NASDAQ:QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), in patients with pulmonary arterial hypertension (
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
8-K/A - Quince Therapeutics, Inc. (0001662774) (Filer)
8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
Citizens JMP downgraded Quince Therapeutics from Mkt Outperform to Mkt Perform
Citizens JMP initiated coverage of Quince Therapeutics with a rating of Mkt Outperform and set a new price target of $9.00
Oppenheimer initiated coverage of Quince Therapeutics with a rating of Outperform and set a new price target of $10.00
Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. Hassan Abolhassani, Assistant Professor of Clinical Immunology and Research Specialists in the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet in Stockholm, Sweden, to the company's Scientific Advisory Board (SAB). Dr. Abolhassani becomes the ninth member to join Quince's SAB, which is comprised of leading experts in Ataxia-Telangiectasia (A-T), biochemistry, neurology, immunology, genetic, hematology, pharmacology, and clinical practice. Dr. Mauro Magnani,
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consultant Paediatric Neurologist at Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, to the company's Scientific Advisory Board (SAB). Dr. Whitehouse joins seven founding members of Quince's SAB comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice. Dr. Mauro Magn
Acquisition includes LAM-001, an inhaled formulation of rapamycin for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome post lung transplant (BOS)$115 million in upfront financing with the potential to receive up to an additional $72 million upon exercise of accompanying warrantsUpfront proceeds from the private placement and existing cash and cash equivalents at closing are expected to fund operations through the end of 2028 and to support multiple expected milestones, including initiation of a Phase 2b trial in PH-ILD with data anticipated in Q1 2028 and delivery of Phase 2 data in BOS in Q
Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that its Board of Directors (the "Board") unanimously approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince's common stock. The dividend distribution will be made on April 17, 2023, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on April 5, 2024.
SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)
SC 13D - Quince Therapeutics, Inc. (0001662774) (Subject)
SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)